top of page
Search
  • rozimorris

EpiEndo Pharmaceuticals to attend SCIENCE4PEACE

SCIENCE4PEACE is a unique manifestation of the Swedish - American Life Science Summit (SALSS) together with The Galien Foundation, taking place in Stockholm, Sweden on the 12th of December during the Nobel festivities


On December 12th, 2022, some of the most distinguished scientists in the world, political leaders and life science executives will gather in Stockholm to talk about the future of healthcare and inspire each other to take action in maintaining science diplomacy.


Perhaps now more than ever, strong global relationships are essential in addressing international challenges. Scientists can be powerful bridge builders, even opening doors between countries that might otherwise remain closed.” Barbro C. Ehnbom, Founder and Chairman of SALSS.


The focus of SALSS this year is Future of Healthcare with speakers specializing in the fields of Precision Medicine and Biotechnology Convergence. Moreover, SALSS will include thought-provoking panel debates on topics such as Tomorrow’s Healthcare, as well as diving deeper into the future of Precision Medicine, and highlighting the need for peace in the scientific community.


Gathering an impressive presence of Nobel Laureates, Academics, Government Officials, Investors, Life Science Executives and Entrepreneurs this year's program features among others Emmanuelle Charpentier, Scientific & Managing Director, Max Planck Unit for the Science of Pathogens, Nobel laureate, Mathias Uhlén, Professor KTH, Dr. William A. Haseltine, President, Access Health International,Thomas Sakmar, Professor Rockefeller University, and Dr. Tim Opler Partner & Co-Founder, Torreya Partners, Chairman of Emerald Bioventures. Presenting companies this year include Akthelia, BioArctic, CELLINK, Devyser, EpiEndo and LIDDS Pharma. CEOs of the companies will showcase their exciting breakthroughs and form new business relationships with investors and other partners.


The future of healthcare is incredibly exciting as current trends will lead to broad social applications of biological breakthroughs, such as gene editing and bioelectronics. Further, new emerging integrated

business models will allow key sectors, including pharmaceuticals, to experience unprecedented value accretion in the decades ahead.” Dr. Tim Opler, Partner & Co-Founder, Torreya Partners, and Chairman of Emerald Bioventures.


For more information on SALSS, please visit www.salss.com and www.science4peace.com or reach out

to us:

Irina Polishchuk +358 468 121 629 polishchuk.iri@gmail.com

Barbro Ehnbom +46 (0) 705 938 335 behnbom@aol.com


Contact

EpiEndo Pharmaceuticals:

Maria Bech, CEO

Email: maria.bech@epiendo.com

Tel: +354 454 0090­­­


Instinctif Partners (media relations):

Rozi Morris / Manisha Kuttetira / Batoul Ali

Email: epiendo@instinctif.com

Tel: +44 20 7457 2020

127 views0 comments
bottom of page